このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

iPACKおよびBiFeSブロックが全膝関節置換術後の回復の質に及ぼす影響 (BiFeS-TKA)

2026年10月2日 更新者:Ahmet Murat Yayik、Ataturk University

iPACKおよび大腿二頭筋短頭(BiFeS)ブロックを内転筋管ブロックと併用した場合の全膝関節置換術後の回復の質への影響:前向き無作為化二重盲検臨床試験

This prospective, randomized, double-blind clinical trial aims to compare the effects of two different posterior knee analgesia techniques-iPACK block (Interspace Between the Popliteal Artery and the Capsule of the posterior Knee) and the Biceps Femoris Short Head (BiFeS) block-when combined with an adductor canal block (ACB) in patients undergoing elective unilateral total knee arthroplasty (TKA). Effective postoperative analgesia is essential for early mobilization, enhanced recovery, and patient satisfaction after TKA. Although ACB provides good anterior knee analgesia while preserving quadriceps strength, additional posterior knee analgesia is often required.

The iPACK block is a commonly used technique that targets the posterior knee capsule, whereas the newer BiFeS block aims to provide more selective posterolateral sensory blockade with potentially reduced risk of motor involvement. However, comparative clinical data between these two techniques are limited.

The primary objective of this study is to evaluate the difference between the iPACK and BiFeS blocks in terms of Quality of Recovery-15 (QoR-15) scores at 24 hours postoperatively. Secondary objectives include comparisons of postoperative pain scores, opioid consumption, time to first analgesic request, quadriceps and anterior tibialis muscle strength, functional test performance, time to mobilization, active range of motion, and the incidence of adverse events.

A total of 74 adult patients scheduled for elective unilateral TKA under spinal anesthesia will be randomized in a 1:1 ratio into two groups: ACB + iPACK block or ACB + BiFeS block. All blocks will be performed under ultrasound guidance by an experienced anesthesiologist. Outcome assessments will be conducted by blinded investigators. The study aims to provide high-quality clinical evidence regarding the effectiveness of the BiFeS block compared to the widely used iPACK technique.

調査の概要

詳細な説明

This study is a prospective, randomized, double-blind, parallel-group, single-center clinical trial designed to compare the effects of two posterior knee analgesia techniques-iPACK block and Biceps Femoris Short Head (BiFeS) block-when combined with an adductor canal block (ACB) on postoperative recovery outcomes following elective total knee arthroplasty (TKA). Postoperative pain after TKA is often severe and can limit early mobilization, delay rehabilitation, and negatively affect recovery. Multimodal analgesia strategies, including regional anesthesia techniques, play an essential role in optimizing postoperative outcomes.

The adductor canal block is widely used because it provides effective anterior knee analgesia while largely preserving quadriceps motor strength. However, it does not adequately address posterior knee pain. The iPACK block is frequently used to supplement ACB, providing analgesia to the posterior knee capsule by targeting the interspace between the popliteal artery and the posterior capsule. The BiFeS block is a newer regional anesthesia technique that involves injection between the femur and the short head of the biceps femoris muscle, targeting terminal sensory branches supplying the posterolateral knee. Cadaveric and early clinical data suggest that the BiFeS block may provide more selective posterior analgesia with limited spread to motor fibers, but comparative clinical data are scarce.

The primary objective of this study is to determine whether the combination of ACB + BiFeS block results in superior quality of recovery compared to ACB + iPACK block, as measured by the QoR-15 score at 24 hours postoperatively. Secondary outcomes include QoR-15 at 48 hours; pain scores at rest and during movement; total opioid consumption at 24 and 48 hours; time to first opioid request; quadriceps and anterior tibialis muscle strength; functional performance assessed using the Timed Up and Go (TUG) and Five Times Sit-to-Stand (FTSST) tests; active knee range of motion; time to first mobilization; and the incidence of adverse events such as nausea, vomiting, pruritus, sedation, neurological symptoms, local anesthetic systemic toxicity, and postoperative falls.

Eligible participants are adults aged 18-75 years undergoing elective primary unilateral TKA under spinal anesthesia, with an ASA physical status of I-III. Exclusion criteria include allergy to study medications, coagulopathy, anticoagulant therapy, severe cardiac, hepatic, or renal dysfunction, pre-existing neuropathic pain, infection at the injection site, neuromuscular disorders of the lower limb, pregnancy, or inability to cooperate with postoperative assessments. Written informed consent will be obtained from all participants. The study has received ethics approval from the Atatürk University Clinical Research Ethics Committee.

Participants will be randomized in a 1:1 ratio using computer-generated block randomization. Both patients and outcome assessors will remain blinded to group assignments. All block procedures will be performed under ultrasound guidance by an experienced anesthesiologist not involved in postoperative assessments. Standardized perioperative management will include spinal anesthesia with hyperbaric bupivacaine, perioperative non-opioid analgesics (paracetamol, dexketoprofen), antiemetic prophylaxis, and postoperative patient-controlled analgesia with fentanyl.

The sample size was calculated based on the minimal clinically important difference (MCID) for the QoR-15 score, assuming an effect size of 8 points, standard deviation of 10, power of 90%, and α = 0.05, resulting in 33 patients per group. Accounting for a 10% dropout rate, 74 patients will be enrolled.

Data will be analyzed using the intention-to-treat principle. Continuous variables will be compared with independent-samples t-tests or Mann-Whitney U tests based on distribution. Mixed-effects models will be used for repeated pain measurements. Categorical variables will be compared using chi-square or Fisher's exact tests. ANCOVA may be applied for adjusted analyses of QoR-15 outcomes.

This trial is expected to contribute important clinical evidence regarding the analgesic effectiveness, functional recovery benefits, and safety profile of the BiFeS block compared with the widely used iPACK block, helping guide postoperative analgesia strategies in total knee arthroplasty.

研究の種類

介入

入学 (実際)

74

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age 18-75 years
  • Scheduled for elective primary unilateral total knee arthroplasty (TKA)
  • Planned spinal anesthesia
  • ASA physical status I-III
  • Ability to understand study procedures and provide written informed consent

Exclusion Criteria:

  • Known allergy or hypersensitivity to local anesthetics or other study medications
  • Coagulopathy or current anticoagulant therapy
  • Severe hepatic, renal, or cardiac failure
  • History of neuropathic pain
  • Infection at the site of proposed nerve block
  • Pre-existing neuromuscular disorders in the lower extremities
  • Inability to cooperate or refusal to participate in the study
  • Pregnancy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Adductor Canal Block + iPACK Block

Participants in this arm will receive an ultrasound-guided adductor canal block (ACB) using 15 mL of 0.25% bupivacaine, followed by an iPACK (Interspace Between the Popliteal Artery and the Capsule of the posterior Knee) block with 25 mL of 0.25% bupivacaine. Blocks will be performed under sterile ultrasound guidance by an experienced anesthesiologist who will not participate in postoperative assessments. All patients will receive standardized spinal anesthesia and perioperative analgesia.

An ultrasound-guided adductor canal block (ACB) will be performed using 15 mL of 0.25% bupivacaine. The probe will be placed on the proximal thigh to visualize the sartorius muscle and femoral artery. The needle will be advanced in-plane into the adductor canal, and correct placement will be confirmed with 2 mL saline before injection. This block aims to provide anterior knee analgesia while preserving quadriceps strength.

他の名前:
  • ACB

The iPACK block will be performed by placing the ultrasound probe at the popliteal region to visualize the popliteal artery and posterior knee capsule. A needle will be advanced in-plane, and 25 mL of 0.25% bupivacaine will be injected between the artery and posterior capsule. This block targets posterior knee pain after total knee arthroplasty without causing motor block.

他の名前:
  • iPACK
  • 膝窩動脈と関節包間ブロック
実験的:Adductor Canal Block + BiFeS Block

Participants in this arm will receive an ultrasound-guided adductor canal block (ACB) using 15 mL of 0.25% bupivacaine, followed by a BiFeS (Biceps Femoris Short Head) block performed by injecting 25 mL of 0.25% bupivacaine into the potential space between the femur and the short head of the biceps femoris muscle. Procedures will be performed under sterile ultrasound guidance by an anesthesiologist not involved in postoperative assessments. All participants will receive standardized spinal anesthesia and perioperative analgesia.

An ultrasound-guided adductor canal block (ACB) will be performed using 15 mL of 0.25% bupivacaine. The probe will be placed on the proximal thigh to visualize the sartorius muscle and femoral artery. The needle will be advanced in-plane into the adductor canal, and correct placement will be confirmed with 2 mL saline before injection. This block aims to provide anterior knee analgesia while preserving quadriceps strength.

他の名前:
  • ACB

The BiFeS block will be performed with the ultrasound probe placed laterally to visualize the femur cortex and the long and short heads of the biceps femoris muscle. The needle will be advanced in-plane into the potential space between the femur and the short head of the biceps femoris. After confirming position with 2 mL saline, 25 mL of 0.25% bupivacaine will be injected. This block provides posterolateral knee analgesia with limited motor involvement.

他の名前:
  • 大腿二頭筋短頭ブロック
  • BiFeS

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Quality of Recovery-15 (QoR-15) Score at 24 Hours
時間枠:24 hours postoperatively

The Quality of Recovery-15 (QoR-15) questionnaire is a validated patient-reported outcome measure assessing overall postoperative recovery across domains such as pain, physical comfort, physical independence, psychological support, and emotional well-being. The total score ranges from 0 to 150, with higher scores indicating better recovery. The outcome compares 24-hour QoR-15 scores between the ACB + iPACK group and the ACB + BiFeS group.

24 hours postoperatively

二次結果の測定

結果測定
メジャーの説明
時間枠
Quality of Recovery-15 (QoR-15) Score at 48 Hours
時間枠:48 hours postoperatively

The QoR-15 questionnaire assesses multidimensional postoperative recovery, with scores ranging from 0 to 150 (higher scores indicate better recovery). This outcome compares 48-hour QoR-15 scores between the ACB + iPACK and ACB + BiFeS groups.

48 hours postoperatively
Pain Scores (VAS) at Rest and During Movement
時間枠:2, 4, 8, 12, 24, and 48 hours postoperatively

Pain intensity will be evaluated using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain). Assessments will be performed at rest and during movement at predefined postoperative time points.

2, 4, 8, 12, 24, and 48 hours postoperatively
Opioid Consumption (Fentanyl PCA)
時間枠:24 and 48 hours postoperatively

Total fentanyl consumption will be extracted from patient-controlled analgesia (PCA) device records, including total delivered dose and number of boluses.

24 and 48 hours postoperatively
Time to First Opioid Request
時間枠:Up to 48 hours postoperatively

The interval between the end of surgery and the patient's first demand for opioid analgesia via PCA will be recorded, indicating the duration of effective postoperative analgesia.

Up to 48 hours postoperatively
Quadriceps and Anterior Tibialis Muscle Strength
時間枠:4, 8, 12, 24, and 48 hours postoperatively

Muscle strength will be assessed using standardized manual muscle testing (0-5 scale) for quadriceps and anterior tibialis muscles. Higher scores reflect greater strength.

4, 8, 12, 24, and 48 hours postoperatively
Timed Up and Go (TUG) Test
時間枠:Postoperative Day 1 and Day 2

Functional mobility will be evaluated using the TUG test, which measures the time required for a participant to stand from a seated position, walk 3 meters, return, and sit down. Shorter times indicate better mobility.

Postoperative Day 1 and Day 2
Five Times Sit-to-Stand Test (FTSST)
時間枠:Postoperative Day 1 and Day 2

Lower extremity functional strength will be assessed by recording the time required to stand up and sit down five consecutive times. Faster performance reflects better function.

Postoperative Day 1 and Day 2
Active Range of Motion (Knee Flexion and Extension)
時間枠:Postoperative Day 1 and Day 2

Knee flexion and extension will be measured using a goniometer to assess active range of motion. Higher degrees indicate improved postoperative mobility.

Postoperative Day 1 and Day 2
Time to First Mobilization
時間枠:Up to 48 hours postoperatively

The time from arrival in the postoperative care unit to the patient's first successful mobilization (standing or walking with assistance) will be recorded.

Up to 48 hours postoperatively
Adverse Events and Complications
時間枠:Up to 48 hours postoperatively

Adverse events including nausea, vomiting, pruritus, sedation, falls, neurological symptoms, block-related complications, and signs of local anesthetic systemic toxicity (LAST) will be monitored.

Up to 48 hours postoperatively

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Ahmet Murat Yayık, Principal Investigator、Ataturk University Department of Anesthesiology and Reanimation
  • スタディディレクター:Mehmet Akif YILMAZ, assistant doctor、Ataturk University Department of Anesthesiology and Reanimation

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月1日

一次修了 (実際)

2026年10月1日

研究の完了 (実際)

2026年10月2日

試験登録日

最初に提出

2025年11月18日

QC基準を満たした最初の提出物

2025年11月18日

最初の投稿 (実際)

2025年11月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data (IPD) will not be shared because the study involves sensitive patient health information, and data confidentiality will be strictly maintained according to institutional ethical guidelines.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する